I am reading a book entitled, SONG OF THE CELL by Pulitzer

New Post Public Reply Private Reply Replies (2) Message Board
dfwl28
890
I am reading a book entitled, SONG OF THE CELL by Pulitzer winner, S. Mukherjee, MD. In the book he recounts a trip wire moment in 2012 +- re: infused cell therapy. Emily Whitehead, age 7, had been diagnosed in 2003 with ALL, acute l. leukemia. The girl had first been treated with traditional chemo and it worked at age 3/4. For a while. In 2012, after failing and near dead, she was enrolled in an infusion therapy "trial" where her T cells had been lab collected and weaponized in a lab against her cancer cells. Trial was at Childrens Hospital of Philadelphia. After the infusion of the directed T cell formula, once again, all seemed to be going well. For a while. Suddenly the child took a turn for the worse. Much worse.

The cause for her downturn to near death status turned out to be a phenomenon all here are familiar with - the cytokine storm. Her IL-6 count was one thousand times higher than normal thanks to the lab infused and rampaging T cells. Consequently, the doc managing the trial assumed the trial was a failure and composed an email proposing the infusion trial termination. Fortunately for the trial, the doc chose to not send the email at that moment in time.

Fate had it that an attending physician at Children's Hospital in Philadelphia who was familiar with arthritic inflammation/conditions and medications and had become aware of a recently developed drug with a potential impact on the inflammation and was able to secure an off-label OK for use of the drug on young Emily. Too make a long story short, the trial was a complete success. Her cancer turned out to be in total remission. She was not dying from cancer. The cytokine storm was killing Emily. She has been cancer free since 2012. Emily was walking within two days of being treated with the off-label medication. What had nearly killed Emily was the cytokine storm not the experimental cancer trial protocol which went on to be a success. The book doesn't mention the drug used that saved Emily's life.

The C storm is everywhere. The cure is under lock and key at the FDA.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

KULR Technology Group Achieves Record Revenue in Q3 Performance

Updated Category News Views 129

An Impressive Revenue Achievement for KULR Technology Group KULR Technology Group, Inc. (NYSE American: KULR), a leader in sustainable energy management, has reported remarkable financial results for its third quarter, showcasing a trend of consistent growth and operational improvements. As the company navigates through the fast-evolving energy landscape, it remains...

Continue Reading
Abeona Therapeutics Finalizes Agreement for $155 Million Sale

Updated Category News Views 250

Abeona Therapeutics Closes $155 Million Priority Review Voucher Deal Abeona Therapeutics Inc. (Nasdaq: ABEO) has made headlines by entering into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for an impressive $155 million. This substantial financial move marks a significant milestone for the company as they navigate the dynamics...

Continue Reading
California BanCorp's Q2 2025 Financial Results Analysis

Updated Category News Views 127

California BanCorp Reports Robust Second Quarter Earnings California BanCorp (NASDAQ: BCAL), the holding company for California Bank of Commerce, recently reported its financial performance for the second quarter, showcasing a solid net income of $14.1 million, translating to $0.43 per diluted share. Financial Highlights of Q2 2025 This impressive figure marks a decrease...

Continue Reading
Starwood Property Trust Succeeds with Private Sustainability Bond Launch

Updated Category News Views 249

Starwood Property Trust, Inc. (NYSE: STWD) completed a $400 million private offering of 6.000% unsecured senior notes due in 2030 back in early 2024, a bold move that made waves on the trading floor. Priced at par value, this maneuver was significant for traders eyeing how such issuances could affect the company’s leverage and cash flow dynamics moving forward....

Continue Reading
FrankSpeech Empowers Creators with Innovative Platform Features

Updated Category News Views 113

FrankSpeech Unveils New Features for Content Creators FrankSpeech is thrilled to announce the launch of exciting new features designed specifically for content creators. This latest initiative marks a significant advancement for the platform, focusing on enhancing video sharing, audience engagement, and monetization avenues. FrankSpeech is dedicated to creating an...

Continue Reading